7 Articles
7 Articles
After decades of failure, treatment against melanoma is very close to being approved.
The mRNA platforms allow the generation of customized vaccines. Immunotherapy has helped open the doors to new molecules. Learn more: Why MSD and Moderna melanoma vaccine can mark a before and after in cancer
The success of a customized mRNA vaccine against melanoma recurrence opens a great space for this technology and could accelerate the career of pharmaceuticals to develop treatments for different types of cancer
Personalized Melanoma Vaccines: What the Phase 3 Intismeran Results Actually Show and What Remains Unknown
A personalized mRNA cancer vaccine has succeeded in a Phase 3 melanoma trial, but that does not mean researchers have developed a vaccine that prevents melanoma—or that all of the important questions have been answered. In August 2026, Moderna and Merck announced that intismeran autogene, formerly known as mRNA-4157 or V940, combined with the immunotherapy drug pembrolizumab (Keytruda) improved outcomes compared with pembrolizumab alone in peopl…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
